Clinical Trial: NCT06138496
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Sun Yat-sen University |
| Information Provided By: | Sun Yat-sen University |
| Last Update Posted: | 2026-04-21 |
Study Overview
Brief Summary
Through the neoadjuvant treatment with a combination of Cadonilimab and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (tumors measuring 4-7 cm located at the renal hilum or with endophytic growth ≥75% or tumors >7 cm)
Official Title
Conditions
Intervention / Treatment
- Drug: Cadonilimab Combined With Lenvatinib
Other Study ID Numbers
- 2023-FXY-117
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Sun Yat-sen University |
| Information Provided By: | Sun Yat-sen University |
| Last Update Posted: | 2026-04-21 |
Study Overview
Brief Summary
Through the neoadjuvant treatment with a combination of Cadonilimab and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (tumors measuring 4-7 cm located at the renal hilum or with endophytic growth ≥75% or tumors >7 cm)
Official Title
Conditions
Intervention / Treatment
- Drug: Cadonilimab Combined With Lenvatinib
Other Study ID Numbers
- 2023-FXY-117